Effect of valsartan on the incidence of diabetes and cardiovascular events. ❋ MD Mark Hyman (2010)
But it may be too soon to give all the credit to ARBs, which include candesartan (Atacand), irbesartan (Avapro), losartan (Cozaar), and valsartan (Diovan). ❋ Unknown (2010)
So does switching from a beta-blocker for high blood pressure to an angiotensin receptor blocker such as losartan or valsartan. ❋ MEHMET C. OZ (2007)
Examples include candesartan (Atacand), irbesartan (Avapro), losartan (Cozaar), and valsartan (Diovan). ❋ M.D. Vivian Pinn (2006)
Diovan Group USD 1.4 billion, -7% cc worldwide sales declined due to the first quarter entry of generic valsartan in select markets. ❋ Unknown (2011)
These include Diovan ® (valsartan), the number one selling branded blood pressure medication worldwide10, Co-Diovan (valsartan and hydrochlorothiazide), a single-pill combination of valsartan with the most widely prescribed diuretic. ❋ Unknown (2011)
Those diagnosed with hypertension are often prescribed one of many blood-pressure lowering drugs such as Novartis's Lotensin or generic benazepril, candesartan, sold as Atacand by AstraZeneca and Takeda, or Novartis' Diovan, known generically as valsartan. ❋ Unknown (2011)
Effectiveness of initiating treatment with valsartan ❋ D H Zappe (2010)
In conclusion, initiating therapy with a combination of valsartan and low-dose HCTZ results in early, improved BP efficacy with similar tolerability as compared with starting treatment with a low or higher dose of valsartan for patients with stage-1 and stage-2 hypertension. ❋ D H Zappe (2010)
Results The cumulative incidence of diabetes was 33. 1% in the valsartan group, as compared with 36. 8% in the placebo group ❋ Unknown (2010)
Conclusions Among patients with impaired glucose tolerance and cardiovascular disease or risk factors, the use of valsartan for 5 years, along with lifestyle modification, led to a relative reduction of 14% in the incidence of diabetes but did not reduce the rate of cardiovascular events. ❋ Unknown (2010)
We studied the effects of valsartan on the occurrence of three coprimary outcomes: the development of diabetes; an extended composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, arterial revascularization, or hospitalization for unstable angina; and a core composite outcome that excluded unstable angina and revascularization. ❋ Unknown (2010)
This prospective, 6-week, multicenter, double-blind study examined the benefits of initiating treatment with combination valsartan ❋ D H Zappe (2010)
/HCTZ required less titration steps compared with the initial valsartan monotherapy groups (63 vs 86, respectively) and the two monotherapy groups, V-low (50.5 and 13.8 %). ❋ D H Zappe (2010)
